Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. - Wikidata - wikimedia - TriplyDB

Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy.

Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy.

http://www.wikidata.org/entity/Q47841043

about

Personal health records: evaluation of functionality and utility The spectrum of thyroid dysfunction in an Australian hepatitis C population treated with combination Interferon-alpha2beta and Ribavirin.Hepatitis C virus infection and thyroid autoimmune disorders: A model of interactions between the host and the environment Hepatitis C virus as a systemic disease: reaching beyond the liver Autoimmune and neoplastic thyroid diseases associated with hepatitis C chronic infection Interferon Alpha Treatment and Thyroid Dysfunction HCV E2 protein binds directly to thyroid cells and induces IL-8 production: A new mechanism for HCV induced thyroid autoimmunity Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug Therapy Autoantibodies in chronic hepatitis C: A clinical perspective Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C Immunological alterations in hepatitis C virus infection.Interferon induced thyroiditis.Hepatitis C and interferon induced thyroiditis.Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences.Spontaneous and antiviral-induced cutaneous lesions in chronic hepatitis B virus infection.Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: a systematic review based analysis Immunological dysfunction during or after antiviral therapy for recurrent hepatitis C reduces graft survival Concurrent autoimmune hepatitis and grave's disease in hepatitis C during pegylated interferon α-2a and ribavirin therapy.Environmental Basis of Autoimmunity.Interferon-alpha induced and ribavirin induced thyroid dysfunction in patients with chronic hepatitis C Thyroid dysfunction in chinese patients with chronic hepatitis C treated with interferon alpha: incidence, long-term outcome and predictive factors.Molecular epidemical characteristics of Lamivudine resistance mutations of HBV in southern China.The etiology of autoimmune thyroid disease: a story of genes and environment Managing thyroid dysfunction in selected special situations.Autoimmune thyroid disorders in hepatitis C virus infection: Effect of interferon therapy Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C.Viruses and thyroiditis: an update.Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy A Potential Link between Environmental Triggers and Autoimmunity.Environmental Issues in Thyroid Diseases Type I interferon therapy and its role in autoimmunity.Autoimmune manifestations in viral hepatitis.The hepatitis C virus infection as a systemic disease.The role of human parvovirus B19 and hepatitis C virus in the development of thyroid disorders.Hepatitis C virus infection of a thyroid cell line: implications for pathogenesis of hepatitis C virus and thyroiditis.Thyroid function is associated with non-alcoholic fatty liver disease in chronic hepatitis B-infected subjects.A Case of Interferon Induced Hypothyroidism.Can pegylated interferon α 2a cause development of thyroid disorders in patients with chronic hepatitis B?Systemic abnormalities in liver disease.Alterations of seminal and hormonal parameters: An extrahepatic manifestation of HCV infection?

P2860

Q24598961-AC508C56-4C4E-4B9C-A33B-18735C6919B2 Q24816546-2384E1FA-D93C-4CBA-86B3-9725A1B80430 Q26775018-52D3B603-ED60-4447-9E7F-C6C08DFEA8E6 Q26776387-12C09A9C-74BC-48C3-9C7C-B49F5CFFF3C2 Q26830844-F03496E1-0B74-492C-984A-7B508AA21C75 Q27483686-4BD0F057-CF02-4421-B9EC-C299D912DA5B Q27487927-5467C201-9244-498C-923E-E750DE4F1C9C Q28073100-A60520F6-7D33-4C39-9267-47B45DC507D7 Q28088556-09209751-35C6-4680-B0EA-0D4C93063DF6 Q28348712-46CCA834-A4B5-4D74-92C6-2D0E9E8E5673 Q33412382-3D4B4FF8-CE40-403F-973A-085FF0CE8505 Q33636049-11267370-60F4-4FFF-8274-1BCE7CB91E79 Q33716540-9CFC967C-EF9F-4711-990F-40525116FB9E Q34308948-7B83A2E4-5048-44DF-BB74-B00046BA7BFD Q34499214-C2A25F78-CC25-4FB6-9ACF-E5BE43BABDE9 Q34577136-47BF74AA-53E2-48DF-9CEE-2C2C2CB4535E Q35212334-B62AB067-F1B8-4695-9402-56D1766E8420 Q35228838-0A5B5D6B-508D-4676-A9A1-EA6E218FD84C Q35638839-FB4E2FC6-E594-4052-9FC8-BB0846060DB8 Q35724605-330B347F-AD06-44E9-8AC6-B8DBFDE013DD Q36329350-E4B0CA58-09BE-43E1-980D-7D6940D4539A Q36516176-2E7ACF4C-8D95-4B73-8F19-687EB9C4AE32 Q36579326-170D73F6-93DB-4D3B-9387-3563B397F814 Q36766694-3C892D2E-31D9-43D1-8A34-BAA15A312500 Q36862264-441B42D0-7067-425E-A09A-39C46D6A8AD1 Q37122206-07C3DB5D-2FD1-420B-A606-C9B24B57F8C8 Q37126267-875598CE-1A5C-4513-9C5D-D11025BF4D04 Q37412136-ABE3AA7F-391E-4DF3-B6CF-7F471FF02430 Q37622097-E3DA9956-F4AC-4EFB-B98D-D2835AC3B95F Q37710354-0EBA56FF-14E1-42C5-AA29-A8236536F909 Q37713730-02B866A0-0751-4E93-8910-4EA655582B70 Q38046450-F113D870-B04C-468B-B8F7-9F9F15DABACE Q38052844-0BEC3FBE-EB75-4735-880F-C6390EF528C3 Q38843347-592513E7-7F96-4FA2-B7B8-BBFF969EA33D Q39222504-A1167039-6C51-4A6A-92BD-F4A1C524B0FA Q41231250-2125FB89-F57C-40B3-A58B-CEAD9D18BD97 Q42207848-C690BAEB-CF6C-4672-B22D-AD4FC77A57F4 Q42210407-9636D197-D575-428C-A5F9-DF7A050F3DCB Q42623529-1FB729CF-AA5C-4B26-A0ED-7353DA16DEA7 Q42774333-41F9406E-2F6D-4657-90F7-A7F9AF8381A2

P2860

Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy.

http://www.wikidata.org/entity/Q47841043

description

1998 nî lūn-bûn

@nan

1998年の論文

@ja

1998年学术文章

@wuu

1998年学术文章

@zh-cn

1998年学术文章

@zh-hans

1998年学术文章

@zh-my

1998年学术文章

@zh-sg

1998年學術文章

@yue

1998年學術文章

@zh

1998年學術文章

@zh-hant

name

Increased risk of autoimmune t ...... continuing interferon therapy.

@en

Increased risk of autoimmune t ...... continuing interferon therapy.

@nl

type

label

Increased risk of autoimmune t ...... continuing interferon therapy.

@en

Increased risk of autoimmune t ...... continuing interferon therapy.

@nl

prefLabel

Increased risk of autoimmune t ...... continuing interferon therapy.

@en

Increased risk of autoimmune t ...... continuing interferon therapy.

@nl

P1433

Q47841043-0DA417B3-48A2-4473-BE7E-0D06E118F776

P1476

Q47841043-82B64534-F40D-4CE3-A5DD-50C3CD315C5F

P2093

Q47841043-0270EEC2-1B99-470C-8AE6-88F9F9AEED2E

Q47841043-2175CB6D-E990-4868-A999-AF28CCA7410E

Q47841043-29FEF1DA-E5C3-49A7-A521-FAF507D577EB

Q47841043-70683DBC-C527-4145-BCBA-1EC07A76B727

Q47841043-75964C91-BB03-43DF-9934-BC4234DFF8F0

Q47841043-8B35CDB8-9D45-49DD-8FD3-1A175CF972E8

Q47841043-C3E49A92-6396-463C-917C-065B226FC5F7

P304

Q47841043-05A7D66D-09F1-4166-83B0-715B4A134A11

P31

Q47841043-C850342A-222D-4649-AC2B-D254C8698DF2

P356

Q47841043-36B76300-E961-4727-A77F-95E36868D055

P407

Q47841043-05902203-B83E-4B48-97E6-8C467BEADCEF

P433

Q47841043-DCCA5417-EA00-4FC5-A170-1D0A8025F042

P478

Q47841043-B5917F0D-E4FB-4B22-9F12-4D5A402B531C

P577

Q47841043-5F1A0DAC-20BA-43E5-88B4-FE80557D76B0

P5875

Q47841043-F4888571-A8B3-41FA-BF4A-55F6DDC73E00

P698

Q47841043-F2422E2E-5549-4ECE-93E5-2305041D8E99

P356

ARCHINTE.158.13.1445

P1433

JAMA Internal Medicine

P1476

Increased risk of autoimmune t ...... continuing interferon therapy.

@en

P2093

Escobar-Jimenez F

http://www.w3.org/2001/XMLSchema#string

Fernandez-Soto L

http://www.w3.org/2001/XMLSchema#string

Gonzalez A

http://www.w3.org/2001/XMLSchema#string

Ocete E

http://www.w3.org/2001/XMLSchema#string

Olea N

http://www.w3.org/2001/XMLSchema#string

Salmeron J

http://www.w3.org/2001/XMLSchema#string

Vazquez R

http://www.w3.org/2001/XMLSchema#string

P304

1445-1448

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHINTE.158.13.1445

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

158

http://www.w3.org/2001/XMLSchema#string

P577

1998-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13620247

http://www.w3.org/2001/XMLSchema#string

P698

9665354

http://www.w3.org/2001/XMLSchema#string